Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous
Pharma
Halozyme CEO targets new deals as IRA uncertainty subsides
As drug developers gain a better grasp of the IRA’s impact, Halozyme has seen a ramp-up in deal discussions over its subcutaneous platform.
Angus Liuu
Oct 14, 2025 9:40am
Halozyme buys Elektrofi for up to $900M
Oct 1, 2025 2:36pm
Merck scores FDA approval for subcutaneous Keytruda
Sep 19, 2025 4:54pm
Roche's high-dose version of Ocrevus flunks phase 3 trial
Apr 2, 2025 3:26pm
Merck lays out subcutaneous Keytruda data amid patent brawl
Mar 27, 2025 11:00am
AstraZeneca inks $1.35B deal for subcutaneous cancer drugs
Mar 17, 2025 10:55am
